Verified news and analysis on AI pharma — clinical milestones, financing, partnerships, and regulation. Updated regularly.
AstraZeneca has entered into a strategic drug discovery collaboration and licensing agreement with Insitro, a leading artificial intelligence therapeutics company. The partnership aims to leverage Insitro's AI-driven platform to accelerate the development of new treatments.
Nvidia-backed Iambic Therapeutics has raised significant funds in its initial public offering to advance its AI-designed cancer drug candidates. The company plans to use the proceeds to fund its early-stage pipeline utilizing its molecular superintelligence platform.
Absci has reported interim Phase 1 data for ABS-201, highlighting a significantly extended half-life. This marks a major milestone as AI-designed biologics transition from computational design to wet-lab validation and clinical proof.
AstraZeneca has engaged in a massive AI drug deal, highlighting the growing role of artificial intelligence in early-stage drug discovery. The agreement tests whether AI can consistently deliver successful treatments through the final stages before regulatory approval.
Insilico Medicine has nominated ISM9546, an AI-driven oral molecular glue and peripheral-restricted VAV1 degrader, as a preclinical candidate for autoimmune diseases. This innovation highlights the company's ongoing efforts to leverage artificial intelligence in discovering novel therapeutic modalities.
Nvidia-backed AI drug developer Iambic Therapeutics has priced its initial public offering, raising approximately $150 million. The clinical-stage biotech company plans to use the funds to advance its AI-driven oncology drug pipeline and will begin trading on the Nasdaq.
Zealand Pharma has partnered with Generate Biomedicines to co-develop protein-based therapeutics for obesity and metabolic diseases using artificial intelligence. The collaboration includes an upfront payment and potential milestone payments totaling nearly $1.2 billion.
Paris-based biotech and AI company Rivercell has raised €22 million to build proprietary cell-response data infrastructure for drug discovery. The funding will support the development of its AI-powered platform designed to accelerate the identification of novel therapeutics.
Chai Discovery has secured a significant partnership with GSK, accelerating its expansion in the AI-driven pharmaceutical space. While the deal underscores the rapid adoption of AI in early drug discovery, experts note that clinical validation remains the ultimate test for these computationally designed molecules.
Iambic Therapeutics has launched a massive initial public offering, bringing significant Wall Street attention to the AI drug discovery sector. The IPO highlights the growing investor confidence in AI-enabled platforms to convert well-funded computational efforts into meaningful clinical progress.